Recombinant PDCD1 (Cemiplimab Biosimilar) antibody

Catalog No. ABIN7488185

The Mammalian Cells Monoclonal anti-PDCD1 (Cemiplimab Biosimilar) antibody is suitable to detect PDCD1 (Cemiplimab Biosimilar) in samples from Human. It has been validated for ELISA.

Quick Overview for Recombinant PDCD1 (Cemiplimab Biosimilar) antibody (ABIN7488185)

Target: PDCD1 (Cemiplimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This PDCD1 (Cemiplimab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-PDCD1 (Cemiplimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb

Characteristics: Antibody Type: IgG4-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for PDCD1 (Cemiplimab Biosimilar)

Target: PDCD1 (Cemiplimab Biosimilar)

Target Type: Biosimilar

Background: REGN-2810,SAR-439684,cemiplimab-rwlc
Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.

CAS-No: 1801342-60-8